It has been reported that RBMS3 plays a tumor suppressor role by downregulating c-Myc and β-catenin [10]; low expression of RBMS3 predicts a poor prognosis in patients with GC and esophageal squamous cell carcinoma [11, 12]. Here, RBMS3 is linked to neoplasm.